Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. gri3d

Gri3D

The industrialization and market entry of a novel bioengineered hydrogel grid to standardize stem cell cultures for precision medicine.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 Gri3D project word cloud

Explore the words cloud of the Gri3D project. It provides you a very rough idea of what is the project "Gri3D" about.

verify    models    entry    tenth    dish    basic    600m    assays    possibilities    automated    precision    opened    manufacturing    corresponds    industry    prototypes    run    instrument    academic    leader    single    organ    strategy    revenues    volume    2016    translated    cumulative    3d    pharmaceutical    sme    introduction    practical    economical    termed    clinical    business    hydra    machine    microembossing    recurrent    groups    units    patient    customers    microstructured    miniature    cultures    capacity    validate    switzerland    gri3d    medicine    care    viability    world    move    handling    base    health    maximum    platform    sa    clients    epfl    successful    industrial    gt    standard    first    stem    ambition    annual    mechanism    liquid    diagnostics    commercializing    tested    line    organoid    expand    biocompatible    bioscience    company    technologies    spin    off    total    producing    feasibility    endless    founded    2021    customer    auomates    sun    organoids    market    2m    intention    generate    initiate    hydrogel    cells   

Project "Gri3D" data sheet

The following table provides information about the project.

Coordinator		 SUN BIOSCIENCE SA 

Organization address
address: EPFL INNOVATION PARK BATIMENT C
city: LAUSANNE
postcode: 1015
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Switzerland [CH]
 Project website http://www.sunbioscience.ch
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing)
2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-03-01   to  2018-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SUN BIOSCIENCE SA CH (LAUSANNE) coordinator 50˙000.00

Map

 Project objective

The ability to generate miniature organ models in a dish, termed organoids, from patient stem cells has opened endless possibilities for applications in precision medicine. SUN bioscience SA, a spin-off company of EPFL in Switzerland, was founded in 2016 with the ambition to move these organoid cultures from basic research to the Health Care industry.

To reach this goal, SUN bioscience has developed Gri3D, a microstructured biocompatible hydrogel platform, and aims to establish this technology as a new standard for growing organoids at industrial scale and precision. Gri3D prototypes have been field tested with over 30 European academic and pharmaceutical R&D groups. In addition, SUN bioscience has developed an industrial automated manufacturing mechanism for Gri3D that is now being translated into the world-wide first machine, Hydra I, that auomates liquid handling with hydrogel microembossing.

The objective of this feasibility study is to verify the technical, economical and practical viability of Gri3D and to ensure its successful market entry in Europe. Specifically, the first step is to validate the production capacity of Hydra I by producing 1’000 Gri3D units, which corresponds to one tenth of the total annual target production volume. In a second step, SUN bioscience aims to validate the market by commercializing these 1’000 Gri3D units to existing customers and to expand its customer base to a total of 20-40 recurrent clients.

According to our current strategy, SUN bioscience will run at maximum single line production capacity with cumulative revenues of >€2M within 3 years after market introduction of Gri3D. The 3D technologies market is expected to reach €600M by 2021. The long-term business objective is to implement organoid assays on Gri3D and to establish SUN bioscience as a leader in clinical diagnostics with the intention to initiate a phase 2 SME instrument project along this path.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GRI3D" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GRI3D" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)

Gri3D (2018)

The industrialization and market entry of a novel bioengineered hydrogel grid to standardize stem cell cultures for precision medicine.

Read More  

PLUGandFLOW (2017)

VessConnect “Plug Flow” innovative technology providing patients a safer, more effective and less costly procedure for vascular anastomosis

Read More  

SUPPLEPRINT (2018)

Super Productive Line Printing Inkjet

Read More